Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innate Pharma Molecule Shows Anti-Tumor Effect in Preclinical Studies

06/10/2021 | 04:32am EDT


ę MT Newswires 2021
All news about INNATE PHARMA
07/16INNATE PHARMA : Corporate Presentation | July 2021
PU
07/06GLOBAL MARKETS LIVE : Facebook, AngloGold, Didi, Weibo, Daimler...
07/06INNATE PHARMA : Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients W..
PU
07/06INNATE PHARMA S A : Trial of Avdoralimab for COVID-19 Did Not Meet Goals; To Sto..
MT
07/06INNATE PHARMA : to Stop Evaluating Antibody for COVID-19 After Mid-Stage Failure
MT
07/06Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pn..
GL
07/06Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID..
CI
07/01INNATE PHARMA : Monthly statement on outstanding equity shares and voting rights
CO
06/22RESULTS PRESENTED AT 16TH INTERNATIO : 00 p.m. CEST / 8:00 a.m. EDT (Form 6-K)
PU
06/22INNATE PHARMA : presents preliminary data from TELLOMAK trial showing clinical r..
GL
More news
Financials
Sales 2021 40,8 M 48,2 M 48,2 M
Net income 2021 -45,8 M -54,1 M -54,1 M
Net cash 2021 27,8 M 32,8 M 32,8 M
P/E ratio 2021 -2,42x
Yield 2021 -
Capitalization 210 M 248 M 248 M
EV / Sales 2021 4,47x
EV / Sales 2022 2,67x
Nbr of Employees 244
Free-Float 75,2%
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 2,66 €
Average target price 5,73 €
Spread / Average Target 116%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
HervÚ Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capi. (M$)
INNATE PHARMA-23.28%248
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-26.60%31 131
SEAGEN INC.-17.54%26 209